Dementia
15 videos · last 6 months shuffled daily, then older videos newest first
▶
51:44 What Should Mild Cognitive Impairment Trials Measure?
University of Bristol senior research associate Victoria presents a core outcome set for mild cognitive impairment trials, developed with people with MCI, family members, researchers and healthcare professionals, in a Dementia Researcher session.
▶
56:31 Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing neflamapimod for Phase 3 in dementia with Lewy bodies, including manufacturing scale-up, partnerships and aligning with regulators on the protocol.
▶
47:10 Oxford Panel on Priorities in Dementia Research
Professor Emma Mead of the ARUK Oxford Drug Discovery Institute leads an Oxford panel on precision diagnosis, adaptive trial design, blood biomarkers and digital home monitoring in dementia, recorded at an Alzheimer's Research UK research day.
▶
41:58 Inside the Alzheimer’s Drug Pipeline: What New Clinical Trials Mean for the Future
Dr. Jeffrey Cummings of the University of Nevada Las Vegas on the Alzheimer's treatment pipeline, where 182 trials evaluated 138 novel drugs in 2025 alone.
▶
1:00:48 TRIALCHAT: AI Chatbots for Dementia Trial Participation
Tim K. Mackey, PhD, MAS, presents TRIALCHAT, agentic AI chatbot tools developed with older adults and caregivers to encourage participation in Alzheimer's disease and related dementias clinical trials, for the a2 Collective.
▶
2:34 Can an AI Robot Improve Life for People With Dementia?
Researchers at UC Davis's Betty Irene Moore School of Nursing are running a study following daily interactions between residents, care partners and Abi, a humanoid AI companion robot.
▶
28:01 Alzheimer's Research Updates from AAIC 2026
Dr. Crystal Glover and Dr. Joshua Grill of UCI discuss advances in Alzheimer's and dementia research and updates on clinical trials from the Alzheimer's Association International Conference 2026 in London, for UCI MIND.
▶
23:05 Moonshots & Milestones: The Future of Neurodegeneration Drug Discovery, AD/PD™ Session Spotlight
A fireside debate from the AD/PD 2026 International Conference on whether the future of neurodegeneration drug discovery lies with startups, big pharma or academia.
▶
5:01 Why "Earlier Diagnosis" Changes What a CNS Trial Needs to Look Like
Francesco Bibbiani and Marty Kraut of Avance Clinical's CNS Center of Excellence discuss how diagnosing Alzheimer's disease before symptoms appear changes trial eligibility, endpoints and design.
▶
28:32 Can Brain Tissue Be Regenerated? Inside the ReGenBrain Trial
Roberta Diaz Brinton, PhD, of the University of Arizona explains the Phase 2 ReGenBRAIN trial testing whether allopregnanolone can repair brain damage and improve thinking in people with mild Alzheimer's who carry APOE ε4, and who can enroll.
▶
43:01 Alzheimer’s and Gum Disease: Exploring the Role of Oral Bacteria in Brain Health
Dr. Michael J. Detke of Lighthouse Pharma discusses the SPRING clinical trial and the investigational oral drug LHP588, which is being studied as a potential way to reduce bacteria-related brain damage.
▶
9:27 Alzheimer's Prevention Trials at Washington University
CBS Sunday Morning visits Washington University School of Medicine in St. Louis, where trials test treatment before symptoms arise in people genetically predisposed to Alzheimer's, and talks with Bill Gates about his Alzheimer's research funding.
▶
37:04 MMSS Keynote: Planning & Executing Effective Clinical Trials for ADRD Research
Dr. Holly Massett of NIH/NIA and Dr. Tamiko MaGee-Rodgers of the Global Alzheimer's Platform discuss the stakeholders involved in trial planning for Alzheimer's disease and related dementias.
▶
7:43 The 'Time Saved' Approach in Alzheimer's Clinical Trials
Guoqiao Wang, PhD, of Washington University School of Medicine introduces 'time saved' as a measure of treatment effect in Alzheimer's disease clinical trials, its limitations and alternative methods, at CTAD 2023.
▶
3:38 Digital Biomarkers in Alzheimer's Disease Clinical Trials
Antonella Chadha Santuccione, MD, co-founder and CEO of the Women's Brain Project and Chief Medical Officer at Altoida, discusses how digital biomarkers could overcome the limits of rating scales in Alzheimer's clinical trials, at AD/PD 2023.